In‐field prostate cancer recurrence following radical prostatectomy and salvage radiation
- 30 November 2024
- journal article
- research article
- Published by Wiley in BJU International
- Vol. 135 (4) , 668-674
Abstract
Objective: To define the natural history, patterns of recurrence and treatment modalities for local prostate cancer (PCa) recurrence following radical prostatectomy (RP) and radiation therapy (RT), and to investigate factors that could predict metastasis‐free survival (MFS) in this unique patient population. Methods: We queried a prospectively maintained PCa registry to identify men developing in‐field recurrence (IFR) following RP and RT from 2008 to 2021 at a single institution. IFR was defined as biopsy‐proven recurrent PCa or the presence of persistent positron emission tomography‐avid lesions in the prior radiation field without evidence of metastasis. Cox regression was conducted to determine predictors of MFS. Kaplan–Meier methods were used to calculate MFS, cancer‐specific survival (CSS) and overall survival (OS) for patients in three primary therapy categories: cryoablation, androgen deprivation therapy (ADT) alone, and surveillance. Results: Of 4575 patients from our registry, 108 (2.3%) with IFR were identified. The median (interquartile range [IQR]) time to IFR from salvage treatment was 78 (50–126) months. A total of 29 patients (26%) were managed with cryoablation, 23 (21%) with ADT, and 28 (25%) with surveillance. The median (IQR) follow‐up was 76 (48–100) months. There were no statistically significant differences in MFS ( P = 0.67) or OS ( P = 0.07) among the three primary treatment cohorts. Patients treated with ADT or cryoablation had longer CSS compared to patients managed with surveillance ( P = 0.047). Conclusions: We found that IFR may present years after completion of primary treatment for PCa. While curative management strategies may be attempted, local and distant metastatic recurrence is common and often requires systemic therapy.Keywords
This publication has 27 references indexed in Scilit:
- Integrating Prostate-specific Antigen Kinetics into Contemporary Predictive Nomograms of Salvage Radiotherapy After Radical ProstatectomyEuropean Urology Oncology, 2022
- Review of commonly used prostate specific PET tracers used in prostate cancer imaging in current clinical practiceClinical Imaging, 2021
- EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate CancerEuropean Urology, 2021
- Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic ReviewEuropean Urology, 2019
- Robotic Stereotactic Retreatment for Biochemical Control in Previously Irradiated Patients Affected by Recurrent Prostate CancerClinical Oncology, 2018
- Stereotactic body re-irradiation therapy for locally recurrent prostate cancer after external-beam radiation therapy: Initial reportCancer/Radiothérapie, 2016
- Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic ReviewEuropean Urology, 2016
- CyberKnife stereotactic radiotherapy for isolated recurrence in the prostatic bedWorld Journal of Urology, 2015
- Disease-Free Survival Following Salvage Cryotherapy for Biopsy-Proven Radio-Recurrent Prostate CancerEuropean Urology, 2011
- When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer?European Journal of Cancer, 2008